SGLT2 inhibitors were introduced to the market over one year ago for the treatment of diabetes mellitus in cats. Since then, we’ve learned a lot about the use of these medications. As a result, patient screening and monitoring protocols have been revised. Join Dr. Cynthia R. Ward, VMD, PhD, DACVIM (SAIM), Professor Emerita, University of Georgia, to discuss SGLT2 inhibitor use, including specific case examples.
Dr. Cynthia Ward received her VMD and PhD degrees from the University of Pennsylvania. She completed residency training at the Veterinary Teaching Hospital at the University of Pennsylvania in small animal internal medicine and a reproductive endocrinology fellowship at the University of Pennsylvania School of Medicine. She was on faculty at the University of Pennsylvania and the University of Georgia and is currently Professor Emerita at the University of Georgia. Dr. Ward is the founder of the UGA Veterinary Diabetes Clinic. She has authored numerous journal articles, book chapters, and research abstracts. Dr. Ward is a Diplomate of the American College of Veterinary Internal Medicine (Small Animal Internal Medicine).
